Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: lactose; purified talc; maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Israel - engelsk - Ministry of Health

mbi pharma ltd., israel - dexamethasone as sodium phosphate - solution for injection - dexamethasone as sodium phosphate 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematologica

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel teva pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.non-small-cell lung cancerdocetaxel teva pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel teva pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel teva pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - european house dust mite extract, quantity: 6 sq-hdm; american house dust mite extract, quantity: 6 sq-hdm - tablet - excipient ingredients: gelatin; sodium hydroxide; purified water; mannitol - allergic rhinitis acarizax is indicated for the treatment of house dust mite (hdm) allergic rhinitis not well controlled despite use of symptom relieving medication in adults and adolescents (? 12 years). allergic asthma acarizax is indicated for the treatment of hdm allergic asthma not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis in adults. patients? asthma status should be carefully evaluated before the initiation of treatment.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite extract, quantity: 5 ir/ml; american house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; phenol; sodium chloride; water for injections; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Israel - engelsk - Ministry of Health

ofek pharma ltd, israel - posaconazole - tablets delayed release - posaconazole 100 mg - posaconazole - treatment of the following fungal infections in adults:- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b.- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patient intolerant to itraconazole.- coccidioidomycosis in patients with disease refractory to amphotericin b, itraconazole or fludonazole or in patient intolerant to these medicinal products.- zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.these are also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplatic syndrome (mds) expected to result in prolonged neutropenia who are at high-risk of developing invasive fungal infections.-hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high-risk of developing invasive fungal infections.

Bangladesh - engelsk - DGDA (Directorate General of Drug Administration)

euro pharma ltd. - ethyl alcohol + isopropyl alcohol - gel - 66 ml + 3.5 ml/100 ml

Bangladesh - engelsk - DGDA (Directorate General of Drug Administration)

euro pharma ltd. - isopropyl alcohol - solution - 75 ml/100 ml

Bangladesh - engelsk - DGDA (Directorate General of Drug Administration)

euro pharma ltd. - dextrose - powder - 100 %